Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;24(11):2241-2249.
doi: 10.1007/s12094-022-02887-8. Epub 2022 Jul 23.

Excess weight and anti-PD-1 immune checkpoint inhibitor's outcomes in non-small cell lung cancer

Jacobo Rogado  1   2 , Fernando Pozo  3 , Kevin Troulé  3 , José Miguel Sánchez-Torres  4   5 , Nuria Romero-Laorden  4   5 , Rebeca Mondejar  4   5   6 , Olga Donnay  4   5 , Anabel Ballesteros  4   5 , Vilma Pacheco-Barcia  4   7 , Javier Aspa  4   8 , Fátima Al-Shahrour  3 , Arantzazu Alfranca  4   9 , Ramon Colomer  4   5   6
Affiliations

Excess weight and anti-PD-1 immune checkpoint inhibitor's outcomes in non-small cell lung cancer

Jacobo Rogado et al. Clin Transl Oncol. 2022 Nov.

Abstract

Purpose: Immune checkpoint inhibitors are one of the most effective treatments available in advanced non-small cell lung cancer. However, at present, there are no clinical or analytical biomarkers that define which patients benefit with certainty from these treatments. In our study, we evaluated whether excess weight could be a good predictive biomarker of benefit from these drugs.

Methods: We studied a population of 79 patients, divided into a study group with 39 patients diagnosed with non-small cell lung cancer treated with immunotherapy and 40 patients in a control group, diagnosed with different advanced cancers, treated with non-immunotherapy treatment. We analyzed according to the presence of excess weight or not, the treatment's outcome in the study group and in the control group (objective response, and progression-free and overall survival).

Results: In our study, we detected a better response rate to immunotherapy in patients with excess weight (62.50 vs 26.08%, OR 4.72, p = 0.02), and a better median progression-free survival (14.19 vs 5.03 months, HR 0.50, p = 0.058) and median overall survival (33.84 months vs 20.76 months, HR 0.43, p = 0.01) in the study group. These findings were specific to the immunotherapy group since in the control group, with patients who did not receive immune checkpoint inhibitors, these findings were not found.

Conclusion: Our study suggests that patients with excess weight who receive anti-PD-1 immune checkpoint inhibitors diagnosed with non-small cell lung cancer have a better outcome. This effect is specific to patients receiving immunotherapy.

Keywords: Excess weight; Immune checkpoint inhibitors; Immunotherapy; Non-small cell lung cancer; Outcome predictors.

PubMed Disclaimer

References

    1. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA. 2005;293(15):1861–7. https://doi.org/10.1001/jama.293.15.1861 (PMID: 15840860). - DOI - PubMed
    1. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309(1):71–82. https://doi.org/10.1001/jama.2012.113905 (PMID:23280227;PMCID:PMC4855514). - DOI - PubMed - PMC
    1. Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083–96. https://doi.org/10.1016/S0140-6736(09)60318-4 (PMID: 19299006; PMCID: PMC2662372). - DOI - PMC
    1. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. International agency for research on cancer handbook working group body fatness and cancer-viewpoint of the IARC working group. N Engl J Med. 2016;375(8):794–8. https://doi.org/10.1056/NEJMsr1606602 (PMID: 27557308 PMCID: PMC6754861). - DOI - PubMed - PMC
    1. Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M, Zoratto F, Marconcini R, Russano M, Zeppola T, Anesi C, Filetti M, Marchetti P, Botticelli A, Gelibter A, De Galitiis F, Vitale MG, Rastelli F, Tudini M, Silva RR, Atzori F, Chiari R, Ricciuti B, De Giglio A, Migliorino MR, Mallardo D, Vanella V, Mosillo C, Bracarda S, Rinaldi S, Berardi R, Natoli C, Ficorella C, Porzio G, Ascierto PA. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. Eur J Cancer. 2020;128:17–26. https://doi.org/10.1016/j.ejca.2019.12.031 (PMID: 32109847). - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources